These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34740140)

  • 1. Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies.
    Wiegand G; May TW; Lehmann I; Stephani U; Kadish NE
    Seizure; 2021 Dec; 93():111-119. PubMed ID: 34740140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of epilepsy with everolimus in tuberous sclerosis.
    Krueger DA; Wilfong AA; Mays M; Talley CM; Agricola K; Tudor C; Capal J; Holland-Bouley K; Franz DN
    Neurology; 2016 Dec; 87(23):2408-2415. PubMed ID: 27815402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
    Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
    Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
    Krueger DA; Wilfong AA; Holland-Bouley K; Anderson AE; Agricola K; Tudor C; Mays M; Lopez CM; Kim MO; Franz DN
    Ann Neurol; 2013 Nov; 74(5):679-87. PubMed ID: 23798472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3.
    Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Herbst F; Peyrard S; Pelov D; French JA
    Epilepsia; 2021 Dec; 62(12):3029-3041. PubMed ID: 34693520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EEG-Findings during long-term treatment with everolimus in TSC-associated and therapy-resistant epilepsies in children.
    Wiegand G; Japaridze N; Gröning K; Stephani U; Kadish NE
    Seizure; 2022 Dec; 103():101-107. PubMed ID: 36370680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan.
    Mizuguchi M; Ikeda H; Kagitani-Shimono K; Yoshinaga H; Suzuki Y; Aoki M; Endo M; Yonemura M; Kubota M
    Brain Dev; 2019 Jan; 41(1):1-10. PubMed ID: 30060984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study.
    Stockinger J; Strzelczyk A; Nemecek A; Cicanic M; Bösebeck F; Brandt C; Hamer H; Intravooth T; Steinhoff BJ
    Epilepsia; 2021 Mar; 62(3):785-794. PubMed ID: 33534134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental outcomes in children/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus.
    Kadish NE; Riedel C; Stephani U; Wiegand G
    Epilepsy Behav; 2020 Oct; 111():107182. PubMed ID: 32535369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
    Okanishi T; Fujimoto A; Nishimura M; Baba S; Itamura S; Okanari K; Enoki H
    Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children.
    Svarrer EMM; Fischer CM; Frederiksen MG; Born AP; Hoei-Hansen CE
    Dan Med J; 2019 Dec; 66(12):. PubMed ID: 31791480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.
    Curatolo P; Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; de Vries PJ; Dlugos DJ; Fan J; Ridolfi A; Pelov D; Voi M; French JA
    Lancet Child Adolesc Health; 2018 Jul; 2(7):495-504. PubMed ID: 30169322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
    French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Berkowitz N; Voi M; Peyrard S; Pelov D; Franz DN
    Lancet; 2016 Oct; 388(10056):2153-2163. PubMed ID: 27613521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
    Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
    Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.
    Krueger DA; Capal JK; Curatolo P; Devinsky O; Ess K; Tzadok M; Koenig MK; Narayanan V; Ramos F; Jozwiak S; de Vries P; Jansen AC; Wong M; Mowat D; Lawson J; Bruns S; Franz DN;
    Eur J Paediatr Neurol; 2018 Nov; 22(6):1066-1073. PubMed ID: 30005812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature.
    Strzelczyk A; Grau J; Bast T; Bertsche A; Bettendorf U; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klotz KA; Kluger G; Knake S; Knuf M; Kurlemann G; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Rosenow F; Ruf S; Sauter M; Schäfer H; Schlump JU; Schubert-Bast S; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Zöllner JP
    Expert Rev Clin Pharmacol; 2021 Jun; 14(6):749-760. PubMed ID: 33792454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.